The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

İlhan E, Güvenç TS, Güzelburç Ö, Altay S, Özer N, Soylu Ö, Hasdemir H, Ergelen M

A fatal complication of tirofiban in an octogenarian: Diffuse alveolar hemorrhage.

Journal of cardiology cases. 2010;2(1):e48-e51

Zhou X, Peng H, Yin Y, Huang H, Zeng J, Ouyang F

Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia.

International journal of cardiology. 2016;206:93-4

Şarlı B, Uğurlu M, Tok A, Dondurmacı E, Sağ Ertürk F

A misleading diagnosis in acute coronary syndrome: tirofiban-induced alveolar hemorrhage.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir. 2015;43(8):753

Guo J, Xu M, Xi Y

Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.

Texas Heart Institute journal. 2012;39(1):99-103

Gill DS, Ng K, Ng KS

Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.

Heart (British Cardiac Society). 2004;90(3):e15

Yilmaz MB, Akin Y, Biyikoglu SF, Guray U, Korkmaz S

Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.

International journal of cardiology. 2004;93(1):81-2

Ali A, Patil S, Grady KJ, Schreiber TL

Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2000;49(2):181-4